Chemohormonal Therapy for Hormone-Sensitive Prostate Cancer: A Review

被引：2
|
作者：
Kyriakopoulos, Christos E. [1 ]
Liu, Glenn [1 ]
机构：
[1] Univ Wisconsin, Carbone Canc Ctr, 600 Highland Ave, Madison, WI 53792 USA
来源：
CANCER JOURNAL | 2016年 / 22卷 / 05期
关键词：
Chemohormonal; Docetaxel; Hormone-sensitive; Prostate cancer; ANDROGEN-DEPRIVATION THERAPY; DOCETAXEL; SURVIVAL; MITOXANTRONE; PREDNISONE; FLUTAMIDE; MEN;
D O I：
10.1097/PPO.0000000000000215
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Ever since the critical role of androgen deprivation therapy for the treatment of metastatic prostate cancer was established, several trials aimed to show an improved outcome with the early introduction of chemotherapy in metastatic disease. Until recently, all these trialsincluding the GETUG-AFU 15 trialfailed to confirm an improvement in survival. The recently published CHAARTED and STAMPEDE trials showed a striking benefit and changed the standard of care for patients with newly diagnosed metastatic prostate cancer. We summarize the evidence that emerged from these trials that support the use of combined chemohormonal therapy in metastatic hormone-sensitive prostate cancer.
引用
收藏
页码：322 / 325
页数：4
相关论文
共 50 条
  • [21] Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review of Economic Evaluations
    Pelloux-Prayer, Remi
    Bataillard, Thomas
    Thiery-Vuillemin, Antoine
    Vincent, Alexandre
    Fagnoni, Philippe
    Nerich, Virginie
    CLINICAL GENITOURINARY CANCER, 2022, 20 (06) : 594 - +
  • [22] Metastatic Hormone-sensitive Prostate Cancer: Current Perspective on the Evolving Therapeutic Landscape
    Hall, Mary E.
    Huelster, Heather L.
    Luckenbaugh, Amy N.
    Laviana, Aaron A.
    Keegan, Kirk A.
    Klaassen, Zachary
    Moses, Kelvin A.
    Wallis, Christopher J. D.
    ONCOTARGETS AND THERAPY, 2020, 13 : 3571 - 3581
  • [23] Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature
    Gravis, Gwenaelle
    Audenet, Francois
    Irani, Jacques
    Timsit, Marc Olivier
    Barthelemy, Philippe
    Beuzeboc, Philippe
    Flechon, Aude
    Linassier, Claude
    Oudard, Stephane
    Rebillard, Xavier
    Richaud, Pierre
    Roupret, Morgan
    Vuillemin, Antoine Thiery
    Vincendeau, Sebastien
    Albiges, Laurence
    Rozet, Francois
    CANCER TREATMENT REVIEWS, 2017, 55 : 211 - 217
  • [24] Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting
    Ng, Kenrick
    Smith, Shievon
    Shamash, Jonathan
    ONCOLOGY AND THERAPY, 2020, 8 (02) : 209 - 230
  • [25] A Territory-wide, Multicenter, Age- and Prostate-specific Antigen-matched Study Comparing Chemohormonal Therapy and Hormonal Therapy Alone in Chinese Men With Metastatic Hormone-sensitive Prostate Cancer
    Teoh, Jeremy Y. C.
    Poon, Darren M. G.
    Lam, Daisy
    Chan, Tim
    Chan, Michelle F. T.
    Lee, Eric K. C.
    Law, Snow
    Chan, Kuen
    Cheng, Nicole M.
    Lai, Kai-Man
    Leung, Chi-Ho
    Ng, Chi-Fai
    CLINICAL GENITOURINARY CANCER, 2019, 17 (01) : E203 - E208
  • [26] Abiraterone acetate plus prednisone/prednisolone in hormone-sensitive and castration-resistant metastatic prostate cancer
    Gschwend, Juergen E
    Miller, Kurt
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2021, 6 (01): : 41 - 49
  • [27] Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis
    Tucci, Marcello
    Bertaglia, Valentina
    Vignani, Francesca
    Buttigliero, Consuelo
    Fiori, Cristian
    Porpiglia, Francesco
    Scagliotti, Giorgio Vittorio
    Di Maio, Massimo
    EUROPEAN UROLOGY, 2016, 69 (04) : 563 - 573
  • [28] Association of serum steroids with survival in metastatic hormone-sensitive prostate cancer
    Mostaghel, Elahe A.
    Wang, Victoria
    Marck, Brett T.
    Sharifi, Nima
    Matsumoto, Alvin M.
    Sweeney, Christopher J.
    ENDOCRINE-RELATED CANCER, 2025, 32 (02)
  • [29] Androgen deprivation therapy ± new antihormonal therapy for the treatment of metastatic hormone-sensitive prostate cancer
    Boegemann, Martin
    UROLOGIE, 2023, 62 (04): : 354 - 359
  • [30] A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer
    Sathianathen, Niranjan J.
    Alarid-Escudero, Fernando
    Kuntz, Karen M.
    Lawrentschuk, Nathan
    Bolton, Damien M.
    Murphy, Declan G.
    Kim, Simon P.
    Konety, Badrinath R.
    EUROPEAN UROLOGY ONCOLOGY, 2019, 2 (06): : 649 - 655
12345